ELYRIS LABS

Elyris Labs

ELYRIS LABS

Physics-driven 3D tumor simulations at scale.

Physics-driven 3D tumor simulations at scale.

Physics-driven 3D tumor simulations at scale.

3D tumor simulation engine that thinks like biology, runs like software.

De-risk your pipeline. Explain why drugs win or fail. Screen at massive scale — instantly.

Oncology, re-engineered.

3D tumor simulation engine that thinks like biology, runs like software.

De-risk your pipeline. Explain why drugs win or fail. Screen at massive scale — instantly. Oncology, re-engineered.

3D tumor simulation engine that thinks like biology, runs like software. De-risk your pipeline. Explain why drugs win or fail. Screen at massive scale — instantly. Oncology, re-engineered.

Raising $2M Pre-Seed

Raising $2M Pre-Seed

Schedule Intro Call

Schedule Intro Call

Contact Us

Contact Us

//01 The Platform

//01 The Platform

See why the drug fails before the wet lab does.

See why the drug fails before the wet lab does.

LURA is Elyris Labs’ state-of-the-art virtual tumor platform — GPU-native simulation that turns months of wet-lab triage into seconds of parallel study. Genotype-conditional selectivity. 3D tissue physics. A governed Pilot Package your reviewers can act on.


Built on modern A100/H100-class fleets, LURA is a step-function increase in preclinical throughput: kill doomed leads before they burn runway, keep capital on compounds that survive real biology, and compress time-to-decision from quarters to a single session.

GPU-accelerated 3D tumor microenvironment simulation — millions of parallel causal experiments in hours, not decades.

We finally let the scientific method win in drug discovery: test vastly more hypotheses, measure real biological mechanism, and explain exactly why drugs succeed or fail — before anyone ever touches a pipette.

Proudly accepted into the NVIDIA Inception Program.

This validates LURA — our GPU-accelerated 3D tumor simulation engine — and unlocks NVIDIA’s top-tier GPU resources, technical support, and co-marketing. We’re already running millions of parallel causal experiments in hours on A100s. With Inception, we’re accelerating even harder: deeper TME modeling, sub-100ms screens, and faster pilot rollouts for oncology teams. Momentum building as we raise $2M to put LURA in drug discovery pipelines worldwide.

Flat dishes. Real tumors. Wrong bets.

Ninety percent of oncology programs fail in human trials. Plastic plates ignore stromal shells, chaotic vasculature, and hypoxic cores. LURA is the computational filter upstream of wet-lab spend — physics and biology, not another scoreboard.

LURA closes the last mile.

Most tools stop at a rank. Teams still assemble the story by hand. LURA screens at campaign scale, promotes survivors, confirms with mechanism and spatial physics, and exports one governed Pilot Package.

//02 Differentiator

//02 Differentiator

Lura's Edge

Lura's Edge

001

Campaign-scale screening

500+ full 3D tumor simulations per second; GPU-accelerated neural architecture; Cloud-scale parallel execution.

002

3D tumor physics

Biomechanical tumor microenvironment modeling; Spatial drug penetration dynamics; Cell-level resolution physics.

003

Mechanistic context

Explainable predictions that reveal active pathways, resistance drivers, and tumor-context effects — not just a score.

004

Governed exports

Pilot Package with provenance + degradation flags

001

Campaign-scale screening

500+ full 3D tumor simulations per second; GPU-accelerated neural architecture; Cloud-scale parallel execution.

002

3D tumor physics

Biomechanical tumor microenvironment modeling; Spatial drug penetration dynamics; Cell-level resolution physics.

003

Mechanistic context

Explainable predictions that reveal active pathways, resistance drivers, and tumor-context effects — not just a score.

004

Governed exports

Pilot Package with provenance + degradation flags

//03 Our Metrics

//03 Our Metrics

//03 Our Metrics

Platform Performance

Platform Performance

Platform Performance

LURA accelerates and de-risks cancer drug discovery and relational mapping with validated, mechanistic simulation.

LURA accelerates and de-risks cancer drug discovery and relational mapping with validated, mechanistic simulation.

0K+

0K+

Rows in one live screen campaign

0K+

0K+

Rows in one live screen campaign

0.0K+

0.0K+

Selectivity evaluations per second

0.0K+

0.0K+

Selectivity evaluations per second

0%

0%

Correlation in Blind Validation

0%

0%

Correlation in Blind Validation

0M+

0M+

Virtual samples per hour

0M+

0M+

Full portfolio screen

Why These Numbers Matter

Why These Numbers Matter

Why These Numbers Matter

Traditional oncology discovery wastes billions on candidates that fail due to unmodeled 3D barriers and mechanisms. LURA's physics + AI approach cuts through that — delivering 10–20× faster insights, validated accuracy, and sub-second responses so teams focus on winners.

ELYRIS Team

OUR TEAM

OUR TEAM

Team member

Aanu Oshakuade

Co-Founder/CEO | Computer Engineering | AI/ML

Team member

Aanu Oshakuade

Co-Founder/CEO | Computer Engineering | AI/ML

Team member

Elisha Sannousi

Co-Founder | Clinical & Translational Engineer (M.S. Translational Medicine, Bioengineering)

Team member

Samuel Tandeka

Co-Founder | Engineering Management & Business Development (M.S. Engineering Management) (B.S. Electrical Eng.)

Team member

Ricardo Silva PhD, MBA, CCE

Principal Advisor | WHO Senior Consultant | Clinical Engineering | Ethical AI | Health Science

Team member

Ricardo Silva PhD, MBA, CCE

Principal Advisor | WHO Senior Consultant | Clinical Engineering | Ethical AI | Health Science

//00 FAQ

LURA Explained

The core questions partners and researchers ask about our 3D neural engine — and how it accelerates cancer drug discovery.

Learn More

Learn More

What is LURA?

LURA is a production-scale 3D physics engine for cancer drug discovery. It builds full, configurable virtual tumor microenvironments and runs millions of virtual experiments to show what actually works — and why — before any wet-lab spend.

Does LURA handle different cancer stages and metastasis?

Yes. Stage I and Stage IV of the same tumor type have completely different parameters — hypoxia, EMT, immune evasion, glucose dependency, etc. Metastatic behavior and TME composition are modeled as distinct, differentiable states so you see exactly how progression changes drug response.

What can I actually test with LURA?

Single agents and full dose-response curves Drug combinations and sequencing Timing & scheduling (e.g., 3 days on, 4 days off) Custom mutations, TME compositions, hypoxia levels, or patient-derived profiles Mechanistic “why it failed” explanations and pathway impacts Rapid repurposing screens across multiple indications

Is the system validated on real cancers and drugs?

Yes — built and tested against hundreds of thousands of historical drug-tumor response measurements across diverse solid tumors. It reproduces known clinical patterns and explains documented failures with clear, physics-based reasoning

How accurate and fast is LURA?

LURA achieves 80–88% correlation with real biological outcomes while delivering hundreds of full 3D tumor simulations per second. A 1,000-compound screen on one tumor model finishes in under 2 minutes; millions of experiments run in hours.

How easy is it for wet-lab teams to use?

Extremely. The V5 dashboard requires no coding. Select or upload your tumor context, choose compounds, run simulations, and get interactive 3D views, dose curves, and plain-English mechanistic summaries. Results are reproducible and ready to share with your team.